We extended our in silico study carried out in collaboration with the Sippl and Schutkowski labs (Martin-Luther-University of Halle-Wittenberg, Germany) to identify nanomolar inhibitors with high selectivity towards the human HDAC11 isoform with marked cytotoxic activity against neuroblastoma cells.